This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07935304 |
|---|---|
| Status | Not yet recruiting |
| Phase | Phase 1 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 90 participants |
| Design | Interventional, Randomized, Parallel, Masking: None |
| Conditions | Healthy |
| Interventions | Eloralintide; Eloralintide |
| Start | Nov 2026 |
| Primary completion | Apr 2027 |
| Study completion | Apr 2027 |
| Results posted | Not yet |
| Registry last updated | Nov 13, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study is to investigate the effects of where Eloralintide is subcutaneously (SC) injected into the body and to investigate how the body processes an intravenous (IV) dose of Eloralintide. Blood tests will be performed to investigate how the study drug affects the body. For each participant, the study will last about 12 weeks and will include a stay in the Clinical Research Unit (CRU) lasting 6 nights.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Pharmacokinetics (PK): Area Under the Plasma Concentration Curve (AUC) of LY3841136 Administered Subcutaneously (SC) | Baseline through Day 57 |
| PK: Maximum Observed Drug Concentration (Cmax) of LY3841136 Administered SC | Baseline through Day 57 |
2 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 18, 2026. See the trial changes feed for what has changed recently.
More trials of Eloralintide
- Eloralintide: Phase 1 Trial in Obesity (NCT05295940)
- Eloralintide and Tirzepatide: Phase 3 Trial (NCT07881432)
- Eloralintide and Tirzepatide: Phase 3 Trial (NCT07881458)
- Eloralintide and Tirzepatide: Phase 2 Trial (NCT06603571)
- Eloralintide: Phase 2 Trial in Obesity (NCT06230523)
- Eloralintide: Phase 1 Trial in Obesity (NCT07808060)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.